“Bimekizumab Maintenance of Response through Three Years in Patients With Moderate to Severe Plaque Psoriasis Who Responded at Week 16: Results from the BE BRIGHT Open-Label Extension Trial”. SKIN The Journal of Cutaneous Medicine 6, no. 6 (November 16, 2022): s65. Accessed April 3, 2025. https://skin.dermsquared.com/skin/article/view/1820.